These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27001536)

  • 1. Quality by Design Approaches to Formulation Robustness-An Antibody Case Study.
    Wurth C; Demeule B; Mahler HC; Adler M
    J Pharm Sci; 2016 May; 105(5):1667-1675. PubMed ID: 27001536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.
    Awotwe-Otoo D; Agarabi C; Wu GK; Casey E; Read E; Lute S; Brorson KA; Khan MA; Shah RB
    Int J Pharm; 2012 Nov; 438(1-2):167-75. PubMed ID: 22944306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.
    Telikepalli S; Kumru OS; Kim JH; Joshi SB; O'Berry KB; Blake-Haskins AW; Perkins MD; Middaugh CR; Volkin DB
    J Pharm Sci; 2015 Feb; 104(2):495-507. PubMed ID: 25522000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrated process analytical technology (PAT) approach to monitoring the effect of supercooling on lyophilization product and process parameters of model monoclonal antibody formulations.
    Awotwe Otoo D; Agarabi C; Khan MA
    J Pharm Sci; 2014 Jul; 103(7):2042-2052. PubMed ID: 24840395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and manufacturability of biologics.
    Shire SJ
    Curr Opin Biotechnol; 2009 Dec; 20(6):708-14. PubMed ID: 19880308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of controlled ice nucleation on process performance and quality attributes of a lyophilized monoclonal antibody.
    Awotwe-Otoo D; Agarabi C; Read EK; Lute S; Brorson KA; Khan MA; Shah RB
    Int J Pharm; 2013 Jun; 450(1-2):70-8. PubMed ID: 23618961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a Biologic Formulation Using Customized Design of Experiment and Novel Multidimensional Robustness Diagrams.
    Maroju RK; Barash S; Brisbane CE
    J Pharm Sci; 2018 Mar; 107(3):797-806. PubMed ID: 29107045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
    Gikanga B; Chen Y; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of formulation variables on protein stability and integrity of a model IgG4 monoclonal antibody and translation to formulation of a model ScFv.
    Gourbatsi E; Povey JF; Smales CM
    Biotechnol Lett; 2018 Jan; 40(1):33-46. PubMed ID: 28939995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality by design approach for formulation development: a case study of dispersible tablets.
    Charoo NA; Shamsher AA; Zidan AS; Rahman Z
    Int J Pharm; 2012 Feb; 423(2):167-78. PubMed ID: 22209997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets.
    Badawy SI; Narang AS; LaMarche KR; Subramanian GA; Varia SA; Lin J; Stevens T; Shah PA
    J Pharm Sci; 2016 Jan; 105(1):168-81. PubMed ID: 26852852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies.
    Brader ML; Estey T; Bai S; Alston RW; Lucas KK; Lantz S; Landsman P; Maloney KM
    Mol Pharm; 2015 Apr; 12(4):1005-17. PubMed ID: 25687223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations.
    Awotwe-Otoo D; Agarabi C; Read EK; Lute S; Brorson KA; Khan MA
    Int J Pharm; 2015 Jul; 490(1-2):341-50. PubMed ID: 25835267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of the Acceptable Ambient Light Exposure during Drug Product Manufacturing for Long-Term Stability of Monoclonal Antibodies.
    Luis LM; Hu Y; Zamiri C; Sreedhara A
    PDA J Pharm Sci Technol; 2018; 72(4):393-403. PubMed ID: 29853610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Freeze drying of L-arginine/sucrose-based protein formulations, part I: influence of formulation and arginine counter ion on the critical formulation temperature, product performance and protein stability.
    Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
    J Pharm Sci; 2015 Jul; 104(7):2345-58. PubMed ID: 25994980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Intercompany Perspective on Biopharmaceutical Drug Product Robustness Studies.
    Morar-Mitrica S; Adams ML; Crotts G; Wurth C; Ihnat PM; Tabish T; Antochshuk V; DiLuzio W; Dix DB; Fernandez JE; Gupta K; Fleming MS; He B; Kranz JK; Liu D; Narasimhan C; Routhier E; Taylor KD; Truong N; Stokes ESE
    J Pharm Sci; 2018 Feb; 107(2):529-542. PubMed ID: 29074375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A design space exploration for control of Critical Quality Attributes of mAb.
    Bhatia H; Read E; Agarabi C; Brorson K; Lute S; Yoon S
    Int J Pharm; 2016 Oct; 512(1):242-252. PubMed ID: 27575657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Stability of a Model IgG3 by DoE-Based Evaluation of Buffer Formulations.
    Chavez BK; Agarabi CD; Read EK; Boyne MT; Khan MA; Brorson KA
    Biomed Res Int; 2016; 2016():2074149. PubMed ID: 27042659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasonic rheology of a monoclonal antibody (IgG2) solution: implications for physical stability of proteins in high concentration formulations.
    Saluja A; Badkar AV; Zeng DL; Kalonia DS
    J Pharm Sci; 2007 Dec; 96(12):3181-95. PubMed ID: 17588261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.